All In Biotech

Free tool

FAERS Monitor: Trazimera

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761081 or its brand name (Trazimera, Trastuzumab-Qyyp). Reports on generic versions are filed under their own applications.

Reports

390

Serious

292

75% of reports

Hospitalization

70

Death reported

42

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • nausea49
  • off label use43
  • chills34
  • diarrhoea33
  • dyspnoea33
  • fatigue31
  • headache31
  • infusion related reaction31
  • pruritus28
  • weight decreased27
  • death25
  • vomiting25
  • malaise22
  • weight increased21
  • pain20

Reports by year received

View as table
YearReports
20151
20193
202029
202154
202259
202385
202490
202550
202619

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,769 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
infusion related reactionSignal3125.218.0699
chillsSignal3415.611.3454
weight decreasedSignal275.23.689
weight increasedSignal215.13.365
pruritusSignal283.92.859
nauseaSignal493.32.681
dyspnoeaSignal333.12.347
vomitingSignal252.92.029
diarrhoeaSignal332.82.036
malaiseSignal222.71.822
headacheSignal312.71.932
off label useSignal432.62.044
fatigueSignal312.11.519
pain201.81.16
death251.61.15

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.